Head-To-Head Comparison: Q BioMed (OTCMKTS:QBIO) & Palvella Therapeutics (NASDAQ:PVLA)

Q BioMed (OTCMKTS:QBIO) and Palvella Therapeutics (NASDAQ:PVLA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, profitability and analyst recommendations.

Risk & Volatility

Q BioMed has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500. Comparatively, Palvella Therapeutics has a beta of 0.1, indicating that its stock price is 90% less volatile than the S&P 500.

Insider & Institutional Ownership

40.1% of Palvella Therapeutics shares are held by institutional investors. 28.2% of Q BioMed shares are held by insiders. Comparatively, 6.4% of Palvella Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Q BioMed and Palvella Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Q BioMed	N/A	N/A	N/A
Palvella Therapeutics	N/A	-80.93%	-59.55%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Q BioMed and Palvella Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q BioMed	0	0	0	0	0.00
Palvella Therapeutics	0	0	7	1	3.13

Palvella Therapeutics has a consensus target price of $44.43, indicating a potential upside of 85.66%. Given Palvella Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Palvella Therapeutics is more favorable than Q BioMed.

Valuation & Earnings

This table compares Q BioMed and Palvella Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q BioMed	$280,000.00	0.05	-$2.05 million	N/A	N/A
Palvella Therapeutics	$42.81 million	6.16	-$24.54 million	($12.10)	-1.98

Q BioMed has higher earnings, but lower revenue than Palvella Therapeutics.

Summary

Palvella Therapeutics beats Q BioMed on 7 of the 12 factors compared between the two stocks.

About Q BioMed

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

About Palvella Therapeutics

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.